polymyositis
Information
- Disease name
- polymyositis
- Disease ID
- DOID:0080745
- Description
- "A myositis that is characterized by muscle weakness affecting both sides of your body." [url:https\://my.clevelandclinic.org/health/diseases/12053-polymyositis, url:https\://www.mayoclinic.org/diseases-conditions/polymyositis/symptoms-causes/syc-20353208]
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT04723303 | Active, not recruiting | Early Phase 1 | Phase 1 Study of ULSC in Patients With Polymyositis (PM) and Dermatomyositis (DM) | October 6, 2021 | April 8, 2024 |
| NCT00001261 | Completed | Phase 2 | Intravenousimmunoglobulin (IVIg) for the Treatment of Inflammatory Myopathies | May 1990 | July 2002 |
| NCT00001265 | Completed | Study and Treatment of Inflammatory Muscle Diseases | January 10, 1992 | April 5, 2024 | |
| NCT00001331 | Completed | Genetic and Family Studies of Inherited Muscle Diseases | May 1993 | March 2002 | |
| NCT00001421 | Completed | Phase 2 | Methimazole to Treat Polymyositis and Dermatomyositis | June 1995 | April 2001 |
| NCT00033891 | Completed | Phase 2 | Infliximab (Remicade ) to Treat Dermatomyositis and Polymyositis | April 10, 2002 | May 20, 2010 |
| NCT00106184 | Completed | Phase 2 | Rituximab for the Treatment of Refractory Adult and Juvenile Dermatomyositis (DM) and Adult Polymyositis (PM) | March 2006 | August 2010 |
| NCT00138983 | Completed | Phase 3 | Prevention of Glucocorticoid-Induced Osteoporosis in Rheumatic Diseases: Alendronate Versus Alfacalcidol. | May 2000 | November 2003 |
| NCT00213629 | Completed | N/A | myoARRAY and TcLandscape Analysis for the Diagnosis of Inflammatory Myopathies | November 2004 | July 2010 |
| NCT00335985 | Completed | Phase 3 | Efficacy and Safety Study of GB-0998 for Treatment of Steroid-resistant Polymyositis and Dermatomyositis (PM/DM) | June 2006 | March 2009 |
| NCT00341679 | Completed | Studies of the Natural History and Pathogenesis of Autoimmune/Connective Tissue Diseases | July 13, 2005 | ||
| NCT00001167 | Completed | Ultrasound Evaluation of Tongue Movements in Speech and Swallowing | August 1979 | November 2004 | |
| NCT00651040 | Completed | Phase 3 | Combined Treatment of Methotrexate + Glucocorticoids Versus Glucocorticoids Alone in Patients With PM and DM | May 2008 | November 2014 |
| NCT00866125 | Completed | Hand Function in Patients With Poly- or Dermatomyositis | April 2002 | August 2002 | |
| NCT00504348 | Completed | Phase 2/Phase 3 | Investigation in Myositis-associated Pneumonitis of Prednisolone And Concomitant Tacrolimus | July 2007 | January 2011 |
| NCT01165008 | Completed | Phase 2/Phase 3 | Anakinra in Myositis | September 2003 | September 2008 |
| NCT01315938 | Completed | Phase 2 | Abatacept Treatment in Polymyositis and Dermatomyositis | January 2011 | November 28, 2013 |
| NCT01415219 | Completed | Phase 2 | Efficacy of an Individual Rehabilitation Program in Polymyositis and Dermatomyositis | March 2008 | December 2013 |
| NCT01432613 | Completed | N/A | Diagnostic Accuracy of Whole Body Magnetic Resonance Imaging in Inflammatory Myopathies | December 22, 2010 | November 26, 2016 |
| NCT01813617 | Completed | Outcome in Patients With Recent Onset Polymyositis and Dermatomyositis | September 2010 | ||
| NCT01906372 | Completed | Phase 2 | Acthar in Treatment of Refractory Dermatomyositis and Polymyositis | September 2013 | May 2016 |
| NCT02043548 | Completed | Phase 2 | Tocilizumab in the Treatment of Refractory Polymyositis and Dermatomyositis | October 1, 2014 | July 31, 2019 |
| NCT02880527 | Completed | Study of the Prevalence of Polymyositis and Dermatomyositis in Normandy | July 2014 | May 2016 | |
| NCT02881450 | Completed | Epidemiological Study of Inflammatory Myopathies in a French Region | January 2012 | August 2019 | |
| NCT02971683 | Completed | Phase 3 | Trial to Evaluate the Efficacy and Safety of Abatacept in Combination With Standard Therapy Compared to Standard Therapy Alone in Improving Disease Activity in Adults With Active Idiopathic Inflammatory Myopathy | May 4, 2017 | August 2, 2022 |
| NCT03414086 | Completed | Predictor of Clinical Response to Acthar in Myositis | November 6, 2017 | July 30, 2022 | |
| NCT03817424 | Completed | Phase 1 | A Study to Evaluate VIB7734 in Participants With Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE), Sjogren's Syndrome, Systemic Sclerosis, Polymyositis, and Dermatomyositis | December 13, 2018 | July 20, 2020 |
| NCT03941184 | Completed | Spontaneous Coronary Artery Dissection (SCAD) and Autoimmunity | January 1, 1995 | November 10, 2020 | |
| NCT04033926 | Completed | Phase 2 | A Phase 2 Study of KZR-616 to Evaluate Safety and Efficacy in Patients With Active Polymyositis or Dermatomyositis | January 14, 2020 | April 6, 2022 |
| NCT04486261 | Completed | N/A | High-intensity Strength Training in Myositis | August 30, 2021 | January 1, 2023 |
| NCT04628936 | Completed | Phase 2 | Open-label Extension to the Phase 2 Crossover Study (PRESIDIO) Evaluating KZR-616 in Patients With PM and DM. | November 4, 2020 | June 12, 2023 |
| NCT04976140 | Completed | Phase 1/Phase 2 | Allogeneic Mitochondria (PN-101) Transplantation for Refractory Polymyositis or Dermatomyositis | December 15, 2021 | October 6, 2023 |
| NCT05637931 | Not yet recruiting | Plexin D1 as a Potential Biomarker inPM/DM | December 25, 2022 | January 25, 2024 | |
| NCT03840928 | Recruiting | PatientSpot Formerly Known as ArthritisPower | April 1, 2015 | March 1, 2025 | |
| NCT01276470 | Recruiting | Environmental Risk Factors for the Anti-synthetase Syndrome | February 9, 2011 | ||
| NCT05650567 | Recruiting | Phase 2 | Study of M5049 in DM and PM Participants (NEPTUNIA) | January 19, 2023 | December 4, 2024 |
| NCT05832034 | Recruiting | Phase 2 | Add-on Intravenous Immunoglobulins in Early Myositis | September 13, 2021 | September 2024 |
| NCT04402086 | Recruiting | Rheumatology Patient Registry and Biorepository | August 4, 2020 | June 1, 2030 | |
| NCT05833711 | Recruiting | Phase 2 | Study Evaluating Efficacy and Safety of Froniglutide (PF1801) in Patients With Idiopathic Inflammatory Myopathy | September 5, 2023 | September 2025 |
| NCT05979441 | Recruiting | Phase 3 | A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Active Idiopathic Inflammatory Myopathy | September 12, 2023 | September 2027 |
| NCT00017914 | Recruiting | Adult and Juvenile Myositis | June 7, 1995 | ||
| NCT06347718 | Recruiting | Phase 1/Phase 2 | CAR-T Cells in Systemic B Cell Mediated Autoimmune Disease | July 17, 2023 | May 31, 2026 |
| NCT05523167 | Recruiting | Phase 2/Phase 3 | A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy. | October 12, 2022 | February 1, 2027 |
| NCT01801917 | Terminated | Phase 2 | Efficacy and Tolerability of BAF312 in Patients With Polymyositis | April 24, 2013 | August 5, 2016 |
| NCT01148810 | Terminated | Phase 2 | Efficacy and Tolerability of BAF312 in Patients With Polymyositis and Dermatomyositis | June 15, 2010 | June 13, 2012 |
| NCT03981744 | Terminated | Phase 3 | A Study of Ustekinumab in Participants With Active Polymyositis and Dermatomyositis Who Have Not Adequately Responded to One or More Standard-of-care Treatments | July 26, 2019 | July 12, 2022 |
| NCT03324152 | Unknown status | N/A | Effects of High-intensity Interval Training (HIIT) in Recent Onset Polymyositis and Dermatomyositis | October 1, 2017 | December 31, 2021 |
| NCT01637064 | Unknown status | Dermatomyositis and Polymyositis Registry | April 2013 | ||
| NCT05027152 | Unknown status | N/A | Muscle Function and Effects of Repetitive Task Training in Patients With Inflammatory Myopaties | September 1, 2021 | September 1, 2023 |
- Disase is a (Disease Ontology)
- DOID:633
- Cross Reference ID (Disease Ontology)
- GARD:7425
- Cross Reference ID (Disease Ontology)
- MESH:D017285
- OrphaNumber from OrphaNet (Orphanet)
- 732
- MedGen concept unique identifier (MedGen Concept name)
- C0085655
- MedGen unique identifier (MedGen Concept name)
- 39086
- ICD10 preferred id (Insert disease from ICD10)
- D0010463
- ICD10 class code (Insert disease from ICD10)
- M33.2
- MeSH unique ID (MeSH (Medical Subject Headings))
- D017285